Ar­cutis wins la­bel ex­pan­sion for younger use of pso­ri­a­sis cream Zo­ryve

Last year
Pharma
FDA+

The re­searchers who res­ur­rect­ed In­re­bic are test­ing a new bone mar­row can­cer drug in space

Last year
R&D

Re­gen­eron pays $100M mile­stone to Al­ny­lam; NIH awards Clene $45M; Bio­haven rais­es $258M

Last year
News Briefing

Mi­rati is once again the cen­ter of buy­out ru­mors, and a ri­val's ad­comm pro­vides a boost

Last year
Pharma

Am­gen clos­es $28B Hori­zon ac­qui­si­tion a month af­ter FTC bat­tle end­ed

Last year
Deals
Pharma

Ab­cam lays out de­tails be­hind $5.7B Dana­her ac­qui­si­tion, takeover at­tempts by founder and for­mer CEO

Last year
People
Deals

A trea­sure trove of new leads on drug tar­gets and bio­mark­ers has been un­cov­ered in a huge pro­teomics study

Last year
R&D

Apel­lis’ Syfovre on the come­back trail from vas­culi­tis wor­ries af­ter $74M in ini­tial Q3 sales

Last year
Pharma

Dave Lennon's CEO ad­ven­ture goes from pre­clin­i­cal to com­mer­cial; GSK vet em­barks on new Odyssey with Gary Glick

Last year
People
Peer Review

FDA's on­col­o­gy ad­comm votes against Am­gen's con­fir­ma­to­ry da­ta for Lumakras in cer­tain types of NSCLC

Last year
FDA+

At­se­na pri­or­i­tizes reti­nal gene ther­a­py pipeline, trims staff as ex­ist­ing in­vestors re­fu­el the biotech 

Last year
People
Cell/Gene Tx

HHS an­nounces move to com­mer­cial dis­tri­b­u­tion for Mer­ck­'s an­tivi­ral Lagevrio

Last year
Pharma

Bausch Health’s Sal­ix tack­les stig­ma around brain con­di­tion caused by acute liv­er dis­ease

Last year
Marketing

Lil­ly says about 70% of pa­tients tak­ing tirzepatide ex­pe­ri­enced an ad­verse event

Last year
R&D

Rea­gan-Udall Foun­da­tion lays out meth­ods for FDA to com­bat mis­in­for­ma­tion

Last year
Pharma
FDA+

Newest FDA-ap­proved opi­oid use dis­or­der drug en­ters the mar­ket with flex­i­ble dos­ing

Last year
Pharma
Marketing

Lon­za boosts ADC sup­ply ca­pac­i­ty through part­ner­ship ex­pan­sion with un­named ma­jor phar­ma

Last year
Deals
Manufacturing

Vi­a­tris down­sizes; Biovec­tra part­ners with Acuitas; Pfiz­er’s Hos­pi­ra re­calls in­jec­tions; WuXi se­cures two new deals

Last year
Manufacturing

Health tech star­tups Com­mure and Athe­las are merg­ing with a $70M boost from Gen­er­al Cat­a­lyst

Last year
Health Tech

Neu­ro­crine re­ports a sec­ond PhI­II suc­cess in con­gen­i­tal adren­al hy­per­pla­sia, this time in chil­dren

Last year
R&D

Longeveron touts PhI­Ia Alzheimer's da­ta, but drug's fu­ture re­mains murky

Last year
R&D

Im­pel con­sid­ers strate­gic al­ter­na­tives, takes out $2.5M loan to con­tin­ue op­er­at­ing

Last year
People
Pharma

Bay­er’s projects with Twist, Evotec; Ab­b­Vie buys out Parkin­son’s drug­mak­er; A new drug dis­cov­ery non­prof­it in ...

Last year
News Briefing

Why An­dreessen Horow­itz's Julie Yoo sees AI as a 'leapfrog op­por­tu­ni­ty' for health­care

Last year
Health Tech
First page Previous page 268269270271272273274 Next page Last page
A service from the Financial Times